Zobrazeno 1 - 10 of 25 pro vyhledávání: '"Hitisha K. Patel"'
1
Akademický článek
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
Autor: Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga, Teeru Bihani
Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-17 (2019)
Abstract Background Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm. With these inhibitor
Externí odkaz: https://doaj.org/article/781ea0c332464bf09c872f6a6b3d11ae
Zobrazit plný text záznamu
2
Data from Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action
Autor: Jamal C. Saeh, Gary Hattersley, Jeffrey L. Brown, Chris P. Miller, Hitisha K. Patel, Dannie Wang, Suqin He, Ziyang Yu
Purpose: Steroidal androgens suppress androgen receptor and estrogen receptor positive (AR/ER+) breast cancer cells and were used to treat breast cancer, eliciting favorable response. The current study evaluates the activity and efficacy of the oral
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8553acfc0ab5010517ce79db2807dde3
https://doi.org/10.1158/1078-0432.c.6525342.v1
Zobrazit plný text záznamu
6
Data from Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Autor: Fiona Garner, Gary Hattersley, Dinesh M. Purandare, Jeffrey L. Brown, Hai Jiang, Nianjun Tao, Heike Arlt, Hitisha K. Patel, Teeru Bihani
Purpose: Estrogen receptor–positive (ER+) breast cancers are typically treated with endocrine agents, and dependence on the ER pathway is often retained even after multiple rounds of antiestrogen therapy. Selective estrogen receptor degraders (SERD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ff3c157a1016b23c8bad8c1454b7e71
https://doi.org/10.1158/1078-0432.c.6525089
Zobrazit plný text záznamu
7
Abstract P6-20-08: Anti-tumor activity of elacestrant (RAD1901) in models harboring ESR1 mutations resistant to standard of care therapies
Autor: Teeru Bihani, Hitisha K. Patel, N Tao, H Arlt
Publikováno v: Cancer Research. 79:P6-20
Background: Estrogen receptor positive (ER+) breast cancers make up approximately 75% of all breast cancers diagnosed and ER, a protein encoded by the ESR1 gene, plays a major role in the initiation, growth and survival of these cancers. Current targ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be5999dfd4b597dc2f386c3a985df603
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-08
Zobrazit plný text záznamu
8
Abstract P4-13-03: Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
Autor: Hitisha K. Patel, H Arlt, N Tao, Teeru Bihani
Publikováno v: Cancer Research. 79:P4-13
Background: Approximately 75% of all breast cancers diagnosed are estrogen receptor-positive (ER+) and currently approved endocrine therapies rely heavily on blocking of the ER signaling pathway. In recent years, the combination of an endocrine agent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5677e1137a8cf7b323083a99c3b39596
https://doi.org/10.1158/1538-7445.sabcs18-p4-13-03
Zobrazit plný text záznamu
9
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Autor: Jeffrey L. Brown, D Purandare, F Garner, Hitisha K. Patel, Gary Hattersley, Teeru Bihani, Hai Jiang, Nianjun Tao, Heike Arlt
Publikováno v: Clinical Cancer Research. 23:4793-4804
Purpose: Estrogen receptor–positive (ER+) breast cancers are typically treated with endocrine agents, and dependence on the ER pathway is often retained even after multiple rounds of antiestrogen therapy. Selective estrogen receptor degraders (SERD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01cbaa074533728bf527fa0934572149
https://doi.org/10.1158/1078-0432.ccr-16-2561
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje